GSK details May share buybacks and voting rights

GSK plc reports that, under its existing share buyback programme and a non-discretionary agreement with Citigroup Global Markets Limited, it repurchased ordinary shares on the London market between 18 and 22 May 2026.

Rhea-AI Filing Summary

GSK plc reports that, under its existing share buyback programme and a non-discretionary agreement with Citigroup Global Markets Limited, it repurchased ordinary shares on the London market between 18 and 22 May 2026.

On those dates, GSK bought between about 329,000 and 339,000 shares per day at volume‑weighted average prices ranging from 1,867.02 GBp to 1,918.46 GBp. Since 11 May 2026, the company has repurchased 3,342,149 ordinary shares, which are being held as treasury shares.

After these purchases, GSK holds 264,720,435 ordinary shares in treasury and has 4,051,501,116 ordinary shares in issue excluding treasury. The total number of voting rights is 4,051,501,116, and GSK states that treasury shares represent 6.53% of voting rights for regulatory disclosure calculations.

Insights

Equity analyst

GSK details routine buybacks that modestly adjust its share count and voting rights.

GSK outlines a series of share repurchases executed between 18 May 2026 and 22 May 2026 under an existing buyback programme and a pre-agreed mandate with Citigroup Global Markets Limited. The filing quantifies daily volumes and prices, plus cumulative purchases since 11 May 2026.

These transactions increase the number of ordinary shares held in treasury to 264,720,435, with total voting rights at 4,051,501,116. GSK notes that treasury shares now account for 6.53% of voting rights, clarifying how investors should calculate disclosure thresholds under UK transparency rules.

The scale of buybacks described here is small relative to the 4,051,501,116 ordinary shares in issue, so the economic impact appears incremental. The main value for investors is precise data on current share count and voting-rights denominators for future regulatory notifications.

Key Figures

Shares repurchased 18 May 2026: 339,102 shares Shares repurchased 22 May 2026: 329,892 shares VWAP range 18–22 May 2026: 1,867.02–1,918.46 GBp/share +5 more

8 metrics

Shares repurchased 18 May 2026 339,102 shares Aggregate ordinary shares purchased on 18 May 2026

Shares repurchased 22 May 2026 329,892 shares Aggregate ordinary shares purchased on 22 May 2026

VWAP range 18–22 May 2026 1,867.02–1,918.46 GBp/share Volume weighted average prices for daily repurchases

Shares bought since 11 May 2026 3,342,149 shares Total ordinary shares repurchased under programme since 11 May 2026

Treasury shares after purchases 264,720,435 shares Ordinary shares held in treasury following May 2026 buybacks

Ordinary shares in issue 4,051,501,116 shares Shares in issue excluding treasury, after reported repurchases

Total voting rights 4,051,501,116 Voting rights denominator for FCA disclosure calculations

Treasury voting-rights percentage 6.53% Percentage of voting rights attributable to treasury-held ordinary shares

Key Terms

Treasury shares, buyback programme, voting rights, Disclosure Guidance and Transparency Rules, +1 more

5 terms

Treasury shares financial

"The purchased shares will be held as Treasury shares."

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

buyback programme financial

"Such share purchases form part of the Company's existing buyback programme"

voting rights financial

"the total number of voting rights in the Company will be 4,051,501,116"

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

Disclosure Guidance and Transparency Rules regulatory

"under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules"

Disclosure guidance and transparency rules are the standards and regulations that require companies to share clear, timely information about their finances, risks, operations and material events. They matter to investors because consistent, honest reporting is like a car’s dashboard — it reveals the data you need to judge safety and performance and make informed buying or selling decisions. Strong disclosure reduces surprises and helps keep markets fair and efficient.

Market Abuse Regulation (EU) No 596/2014 regulatory

"In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share repurchases did GSK (GSK) report for May 2026?

GSK reported buying ordinary shares on 18–22 May 2026 under its existing buyback programme. It repurchased roughly 329,000–339,000 shares per day at volume‑weighted average prices between 1,867.02 GBp and 1,918.46 GBp, all to be held as treasury shares.

How many GSK (GSK) shares have been repurchased since 11 May 2026?

Since 11 May 2026, GSK has repurchased 3,342,149 ordinary shares. These shares were bought under the company’s existing buyback programme and are held as treasury shares, which reduces the freely traded share count while not carrying voting rights like shares in public hands.

What is GSK’s current total number of voting rights after these buybacks?

Following the reported purchases, GSK states it has 4,051,501,116 total voting rights. This figure matches the number of ordinary shares in issue excluding treasury shares and is the denominator shareholders should use for UK disclosure and transparency notification calculations.

How many GSK shares are now held in treasury and what percentage of voting rights is this?

GSK holds 264,720,435 ordinary shares in treasury after these transactions. The company confirms this treasury position represents 6.53% of the total voting rights, a percentage calculated under DTR 5.5.1R for UK disclosure guidance and transparency rule purposes.

At what price range did GSK repurchase its shares in May 2026?

During 18–22 May 2026, GSK’s daily volume‑weighted average repurchase prices ranged from 1,867.02 GBp to 1,918.46 GBp per share. Each day’s purchases also had disclosed lowest and highest prices within that general range on the London Stock Exchange and CBOE Europe venues.

Why does GSK highlight the 4,051,501,116 voting rights figure?

GSK highlights 4,051,501,116 as the total number of voting rights so shareholders can use it as the denominator for regulatory threshold calculations. Under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules, investors must reference this figure when assessing reportable holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/26/2026 - 10:17 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Transaction in own shares

GSK plc (the "Company") announces today acting through Citigroup Global Markets Limited (the "Broker"), it has purchased the following number of the Company's ordinary shares of 31¼ pence each.

Date of purchase	Aggregate number of ordinary shares of 31 ¼ pence each purchased	Lowest price paid per share (GBp)	Highest price paid per share (GBp)	Volume weighted average price paid per share (GBp)
18 May 2026	339,102	1,847.00	1,882.00	1,867.02
19 May 2026	336,572	1,872.50	1,909.00	1,890.81
20 May 2026	332,060	1,886.00	1,914.00	1,899.43
21 May 2026	332,672	1,883.00	1,918.50	1,902.38
22 May 2026	329,892	1,906.00	1,927.00	1,918.46

The purchased shares will be held as Treasury shares.

Such share purchases form part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 8 May 2026, as announced on 11 May 2026.  Since 11 May 2026 the Company has purchased 3,342,149 ordinary shares.

Following the above purchases, the Company will hold 264,720,435 ordinary shares in treasury and have 4,051,501,116 ordinary shares in issue (excluding Treasury shares).

Following the above purchases, the total number of voting rights in the Company will be 4,051,501,116. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company confirms that, in accordance with DTR 5.5.1R, following the above purchases the percentage of voting rights attributable to the ordinary shares held in treasury is 6.53 per cent.

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended, a full breakdown of the individual purchases of ordinary shares made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) is set out in the Schedule to this announcement, available via the link below:

http://www.rns-pdf.londonstockexchange.com/rns/7364F_1-2026-5-26.pdf

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

GSK enquiries
Media:	Tim Foley	+44 (0) 20 8047 5502	(London)
	Kathleen Quinn	+1 202 603 5003	(Washington DC)
Investor Relations:	Constantin Fest	+44 (0) 7831 826525	(London)
	James Dodwell	+44 (0) 20 8047 2406	(London)
	Mick Readey	+44 (0) 7990 339653	(London)
	Steph Mountifield	+44 (0) 7796 707505	(London)
	Sam Piper	+44 (0) 7824 525779	(London)
	Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
	Frannie DeFranco	+1 215 751 3126	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and GSK's Q1 Results for 2026.

Registered in England & Wales:

No. 3888792

Registered Office:

9 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: May 26, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc